StemCell InstituteStemCell Institute Inc.7096東証グロース医薬品FY ending Mar 2026, consolidated, J-GAAP
Out of every ¥100 of sales, about ¥7 is left as operating profit. Revenue changed +4.9% from the prior year, operating profit -51.6%.
Net margin × asset turnover = ROA; ROA × financial leverage = ROE
Denominators: ending assets and ending equity. Derived from reported values; ROE is shown only for positive profit and equity.
| Period | Net margin | Asset turnover | ROA | Financial leverage | ROE |
|---|---|---|---|---|---|
| 2022 | 7.5% | 0.34× | 2.6% | 2.48× | 6.4% |
| 2023 | 9.5% | 0.38× | 3.6% | 2.50× | 9.0% |
| 2024 | 12.5% | 0.40× | 5.0% | 2.51× | 12.7% |
| 2025 | 14.4% | 0.38× | 5.5% | 2.67× | 14.7% |
| 2026 | 5.5% | 0.35× | 1.9% | 3.01× | 5.8% |
Financial leverage can raise ROE; a higher value alone does not describe a company's overall condition.
Annual trends in tangible-asset ratios and goodwill balance.
Ratios are derived from reported values. Goodwill is shown only when separately reported; it is not inferred from combined intangible assets. Definition
Track R&D investment and how long operating capital remains tied up before sales turn into cash.
R&D is shown only for years with machine-readable disclosure. Days are estimates using year-end receivables, inventory and payables divided by annual revenue or cost of sales; financial companies are excluded.
| Item | FY ending Mar 2022 | FY ending Mar 2023 | FY ending Mar 2024 | FY ending Mar 2025 | FY ending Mar 2026 |
|---|---|---|---|---|---|
| Revenue | 1,782 | 2,091 | 2,481 | 2,679 | 2,811 |
| Cost of revenue | 671 | 755 | 905 | 987 | 1,099 |
| Gross profit | 1,111 | 1,336 | 1,576 | 1,692 | 1,712 |
| SG&A | 884 | 1,038 | 1,162 | 1,274 | 1,510 |
| Operating income | 227 | 298 | 414 | 419 | 203 |
| Pretax income | 213 | 279 | 441 | 566 | 218 |
| Income tax | 79 | 81 | 130 | 180 | 87 |
| Net income attributable to owners | 134 | 198 | 311 | 386 | 156 |
| Operating margin | 12.7% | 14.2% | 16.7% | 15.6% | 7.2% |
Year-end figures from filings. Unreported items are omitted. Interest-bearing debt excludes lease liabilities.
Each bar totals 100% of assets; other is the residual.
| Item | FY ending Mar 2022 | FY ending Mar 2023 | FY ending Mar 2024 | FY ending Mar 2025 | FY ending Mar 2026 |
|---|---|---|---|---|---|
| Cash and equivalents | ¥3.51B | ¥3.32B | ¥2.85B | ¥3.2B | ¥2.83B |
| Total assets | ¥5.22B | ¥5.81B | ¥6.54B | ¥7.5B | ¥8.12B |
| Net assets | ¥2.1B | ¥2.3B | ¥2.69B | ¥2.63B | ¥3.07B |
| Share capital | ¥704.8M | ¥704.8M | ¥704.8M | ¥704.8M | ¥704.8M |
| Property, plant and equipment | ¥647.6M | ¥648.1M | ¥665.2M | ¥1.16B | ¥1.38B |
| Intangible assets excluding goodwill | ¥24.7M | ¥24.5M | ¥41.6M | ¥132.4M | ¥225.6M |
| Investment securities | ¥105.1M | ¥243.3M | ¥512.9M | ¥647.9M | ¥830.1M |
| Current assets | ¥4.18B | ¥4.55B | ¥4.52B | ¥5.17B | ¥5.31B |
| Current liabilities | ¥3.05B | ¥3.43B | ¥3.76B | ¥4.32B | ¥4.53B |
| Long-term borrowings | — | — | — | ¥437.6M | ¥377.1M |
| Total liabilities | ¥3.11B | ¥3.51B | ¥3.85B | ¥4.87B | ¥5.05B |
| Non-controlling interests | — | — | — | — | ¥392.4M |
| Equity attributable to owners of parent | ¥2.1B | ¥2.3B | ¥2.61B | ¥2.65B | ¥2.7B |
| Retained earnings | ¥809.4M | ¥1.01B | ¥1.32B | ¥1.45B | ¥1.6B |
| Treasury stock | — | -¥91K | -¥91K | -¥94.1M | -¥200.1M |
EDINET (FSA Japan)
有価証券報告書－第27期(2025/04/01－2026/03/31)
EDINET (FSA Japan)
有価証券報告書－第26期(2024/04/01－2025/03/31)
EDINET (FSA Japan)
有価証券報告書－第25期(2023/04/01－2024/03/31)
EDINET (FSA Japan)
有価証券報告書－第24期(2022/04/01－2023/03/31)
EDINET (FSA Japan)
有価証券報告書－第23期(令和3年4月1日－令和4年3月31日)
EDINET (FSA Japan)
有価証券報告書－第22期(令和2年4月1日－令和3年3月31日)
Extracted from XBRL: 49 / Derived from other figures: 1
Spotted an error? Report it (corrections keep the original record)
Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.